Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Drug Development Consulting Holding ApS
APS
Active
Advertising protection
CVR 42285722
Smedeland 36, 2600
Glostrup
Activities of holding companies
·
NACE 6421
Est. 2021 · 5 years old
— employees
Monitor
Share
Denmark
/
Companies
/
Activities of holding companies
/
Drug Development Consulting Holding ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
EBITDA
DKK millions
0M
-0M
-1M
-1M
-1M
0M
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
Income statement
DKK thousands
Item
2021
2022
2023
2024
Gross profit
40
-58
-53
-116
Staff expenses
-0
-0
-0
-0
EBITDA
40
-58
-53
-116
Depreciation & amort.
-0
-0
-0
-0
EBIT
40
-58
-53
-116
Net financials
-15.752
-11.814
-9.329
-13.211
Profit before tax
-15.712
-11.872
-9.382
-13.327
Tax
-0
2
-6
-25
Net profit
-15.712
-11.874
-9.376
-13.302
Balance sheet
DKK thousands
Item
2021
2022
2023
2024
Total assets
70.809
72.021
70.482
79.167
Equity
70.809
71.988
70.460
79.145
Long-term debt
0
0
0
0
Short-term debt
0
33
22
22
Total debt
0
33
22
22
Financial ratios
5-year trend
EBITDA margin (of gross profit)
-11600000.0%
This company
2021
2024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
2021
2024
Return on equity
-16.8%
This company
18.4%
Market median
-191% vs market
2021
2024
Net profit margin (of gross profit)
-1330200000.0%
This company
2021
2024
Asset turnover (of gross profit)
-0.00×
This company
2021
2024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
2021
2024
Annual reports & filings
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-04-07 – 2021-12-31
View
PDF
More on Drug Development Consulting Holding ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
